Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28960166 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL23783392 | 0.84 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL30207477 | 0.84 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31701825 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNATHRBKMT2A | |
| SCHEMBL994347 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL29536266 | 0.84 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31334845 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL29179922 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL22179574 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNATHRBPOLB | |
| SCHEMBL31548463 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNATHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| WO-2023039208-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-20240245677-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023039208-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245677-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRIX1, BRWD1 | ALDH1A1 4393/4885MAPT 1749/4885LMNA 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.